buyWeak
Brad Hively bought $50k of STLN
director at Oncology Institute, Inc.. 300,000 shares at an average of $0.17, traded Nov 26, 2024, filed Dec 2, 2024.
Conviction score
32Value
$50k
300,000 shares
Holdings after
666,753
+82% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleDirector
- +7Trade size$50k at market
- +10Relative to holdingsHoldings up 82%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001799191-24-000063, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 12, 2024 | JOther Common stock | -353,450 | $0.00 | $0 | 366,753 | Dec 2, 2024 |
| Nov 26, 2024 | POpen-market purchase Common stock | +250,000 | $0.17 | $43k | 616,753 | Dec 2, 2024 |
| Dec 2, 2024 | POpen-market purchase Common stock | +50,000 | $0.15 | $7,500 | 666,753 | Dec 2, 2024 |
Related signals
Other insiders at Oncology Institute, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 65Notable | Oncology Institute, Inc. | Richard A Barasch director | $1.4M 1,358,448 shares | +326% | |
| 43Moderate | Oncology Institute, Inc. | Robert Ross Carter Chief Financial Officer | $9,434 9,056 shares | +30% | |
| 38Weak | Oncology Institute, Inc. | Jeremy Castle Chief Operating Officer | $9,434 9,056 shares | +11% | |
| 30Weak | Oncology Institute, Inc. | Brad Hively director | $9,434 9,056 shares | +1% | |
| 42Moderate | Oncology Institute, Inc. | Karen Marie Johnson director | $38k 36,224 shares | +22% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.